A citation-based method for searching scientific literature

Mariese A Hely, John G L Morris, Wayne G J Reid, Robert Trafficante. Mov Disord 2005
Times Cited: 691







List of co-cited articles
826 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Susan H Fox, Regina Katzenschlager, Shen-Yang Lim, Brandon Barton, Rob M A de Bie, Klaus Seppi, Miguel Coelho, Cristina Sampaio. Mov Disord 2018
327
16

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.
Mariese A Hely, Wayne G J Reid, Michael A Adena, Glenda M Halliday, John G L Morris. Mov Disord 2008
13

5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.
Cynthia Kwan, Imane Frouni, Dominique Bédard, Stephen G Nuara, Jim C Gourdon, Adjia Hamadjida, Philippe Huot. Exp Brain Res 2019
17
64

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Klaus Seppi, K Ray Chaudhuri, Miguel Coelho, Susan H Fox, Regina Katzenschlager, Santiago Perez Lloret, Daniel Weintraub, Cristina Sampaio. Mov Disord 2019
324
11

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Jeffrey Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi-Burris, Anne Corbett, Rohit Dhall, Clive Ballard. Lancet 2014
383
11

The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset.
Adjia Hamadjida, Stephen G Nuara, Dominique Bédard, Fleur Gaudette, Francis Beaudry, Jim C Gourdon, Philippe Huot. Neuropharmacology 2018
24
41

Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism.
Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G Nuara, Jim C Gourdon, Francis Beaudry, Philippe Huot. Neuropharmacology 2019
18
55

Non-motor symptoms of Parkinson's disease: diagnosis and management.
K Ray Chaudhuri, Daniel G Healy, Anthony H V Schapira. Lancet Neurol 2006
10


The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
Adjia Hamadjida, Stephen G Nuara, Nicolas Veyres, Imane Frouni, Cynthia Kwan, Lamia Sid-Otmane, Mery-Jane Harraka, Jim C Gourdon, Philippe Huot. Psychopharmacology (Berl) 2017
26
38

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Manolo Carta, Thomas Carlsson, Deniz Kirik, Anders Björklund. Brain 2007
467
9

Parkinson disease.
Werner Poewe, Klaus Seppi, Caroline M Tanner, Glenda M Halliday, Patrik Brundin, Jens Volkmann, Anette-Eleonore Schrag, Anthony E Lang. Nat Rev Dis Primers 2017
9

Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
Lamia Sid-Otmane, Adjia Hamadjida, Stephen G Nuara, Dominique Bédard, Fleur Gaudette, Jim C Gourdon, Véronique Michaud, Francis Beaudry, Michel Panisset, Philippe Huot. Eur J Pharmacol 2020
13
69

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
Susan H Fox, Naomi Visanji, Gaby Reyes, Philippe Huot, Jordi Gomez-Ramirez, Tom Johnston, Jonathan M Brotchie. Can J Neurol Sci 2010
52
17

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
C Warren Olanow, Karl Kieburtz, Olivier Rascol, Werner Poewe, Anthony H Schapira, Murat Emre, Helena Nissinen, Mika Leinonen, Fabrizio Stocchi. Mov Disord 2013
276
8

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Rajesh Pahwa, Caroline M Tanner, Robert A Hauser, Stuart H Isaacson, Paul A Nausieda, Daniel D Truong, Pinky Agarwal, Keith L Hull, Kelly E Lyons, Reed Johnson,[...]. JAMA Neurol 2017
98
8

Clinical diagnostic criteria for dementia associated with Parkinson's disease.
Murat Emre, Dag Aarsland, Richard Brown, David J Burn, Charles Duyckaerts, Yoshikino Mizuno, Gerald Anthony Broe, Jeffrey Cummings, Dennis W Dickson, Serge Gauthier,[...]. Mov Disord 2007
8

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Naomi P Visanji, Jordi Gomez-Ramirez, Tom H Johnston, Donna Pires, Valerie Voon, Jonathan M Brotchie, Susan H Fox. Mov Disord 2006
71
11

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
François Tison, Charlotte Keywood, Mark Wakefield, Franck Durif, Jean-Christophe Corvol, Karla Eggert, Mark Lew, Stuart Isaacson, Erwan Bezard, Sonia-Maria Poli,[...]. Mov Disord 2016
87
9

Levodopa and the progression of Parkinson's disease.
Stanley Fahn, David Oakes, Ira Shoulson, Karl Kieburtz, Alice Rudolph, Anthony Lang, C Warren Olanow, Caroline Tanner, Kenneth Marek. N Engl J Med 2004
8

Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Santiago Perez-Lloret, Olivier Rascol. J Neural Transm (Vienna) 2018
41
19

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A J Hughes, S E Daniel, L Kilford, A J Lees. J Neurol Neurosurg Psychiatry 1992
7

Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
7

ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia.
Rajesh Pahwa, Robert A Hauser. JAMA Neurol 2017
10
70

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Philippe Huot, Tom H Johnston, James B Koprich, Susan H Fox, Jonathan M Brotchie. Neuropharmacology 2012
33
21

Parkinson's disease: clinical features and diagnosis.
J Jankovic. J Neurol Neurosurg Psychiatry 2008
7


UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
Philippe Huot, Tom H Johnston, Katie D Lewis, James B Koprich, M Gabriela Reyes, Susan H Fox, Matthew J Piggott, Jonathan M Brotchie. Neuropharmacology 2014
38
18

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
Philippe Huot, Tom H Johnston, Katie D Lewis, James B Koprich, M Gabriela Reyes, Susan H Fox, Matthew J Piggott, Jonathan M Brotchie. J Neurosci 2011
56
12

Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Adjia Hamadjida, Stephen G Nuara, Dominique Bédard, Imane Frouni, Cynthia Kwan, Jim C Gourdon, Philippe Huot. Naunyn Schmiedebergs Arch Pharmacol 2018
12
58

Parkinsonism: onset, progression and mortality.
M M Hoehn, M D Yahr. Neurology 1967
7


Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.
Irene Litvan, Jennifer G Goldman, Alexander I Tröster, Ben A Schmand, Daniel Weintraub, Ronald C Petersen, Brit Mollenhauer, Charles H Adler, Karen Marder, Caroline H Williams-Gray,[...]. Mov Disord 2012
7

Impact of the motor complications of Parkinson's disease on the quality of life.
Stéphane Chapuis, Lemlih Ouchchane, Olivier Metz, Laurent Gerbaud, Franck Durif. Mov Disord 2005
357
6



Cognitive decline in Parkinson disease.
Dag Aarsland, Byron Creese, Marios Politis, K Ray Chaudhuri, Dominic H Ffytche, Daniel Weintraub, Clive Ballard. Nat Rev Neurol 2017
441
6

Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
W G J Reid, M A Hely, J G L Morris, C Loy, G M Halliday. J Neurol Neurosurg Psychiatry 2011
122
6

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.
Christopher G Goetz, Werner Poewe, Olivier Rascol, Cristina Sampaio, Glenn T Stebbins, Carl Counsell, Nir Giladi, Robert G Holloway, Charity G Moore, Gregor K Wenning,[...]. Mov Disord 2004
6

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Rajesh Pahwa, Caroline M Tanner, Robert A Hauser, Kapil Sethi, Stuart Isaacson, Daniel Truong, Lynn Struck, April E Ruby, Natalie L McClure, Gregory T Went,[...]. Mov Disord 2015
99
6

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Per Svenningsson, Carl Rosenblad, Karolina Af Edholm Arvidsson, Klas Wictorin, Charlotte Keywood, Bavani Shankar, David A Lowe, Anders Björklund, Håkan Widner. Brain 2015
116
6

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.
Paolo Barone, Angelo Antonini, Carlo Colosimo, Roberto Marconi, Letterio Morgante, Tania P Avarello, Eugenio Bottacchi, Antonino Cannas, Gabriella Ceravolo, Roberto Ceravolo,[...]. Mov Disord 2009
873
6

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Susan H Fox, Naomi P Visanji, Tom H Johnston, Jordi Gomez-Ramirez, Valerie Voon, Jonathan M Brotchie. Arch Neurol 2006
46
13


Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
Matthieu F Bastide, Wassilios G Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla,[...]. Prog Neurobiol 2015
273
6

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Christopher Kobylecki, Michael P Hill, Alan R Crossman, Paula Ravenscroft. Mov Disord 2011
44
13

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Philippe Huot, Tom H Johnston, James B Koprich, Susan H Fox, Jonathan M Brotchie. Pharmacol Rev 2013
207
6

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Christopher G Goetz, Philippe Damier, Christine Hicking, Eugene Laska, Thomas Müller, C Warren Olanow, Olivier Rascol, Hermann Russ. Mov Disord 2007
205
6

The scientific and clinical basis for the treatment of Parkinson disease (2009).
C Warren Olanow, Matthew B Stern, Kapil Sethi. Neurology 2009
527
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.